Document is current
Any future updates will be listed below
-
Authors
Cheves, Emily https://orcid.org/0000-0001-8801-0411
Potter, Sarah Nelson https://orcid.org/0000-0002-8640-8992
Kutsa, Oksana https://orcid.org/0000-0002-8148-6166
Andrews, Sara M. https://orcid.org/0000-0003-0218-0976
Gwaltney, Angela https://orcid.org/0000-0002-2305-7187
Wheeler, Anne https://orcid.org/0000-0003-2693-5616
-
Funding
Funding for this research was provided by:
National Center on Birth Defects and Developmental Disabilities (RTOI 2010-999-01.)
RTI International
- License Information
-
More Information
Article History
Accepted: 2 November 2024
First Online: 25 November 2024
Declarations
:
: AW has received funding from the Angelman Syndrome Foundation, Foundation for Angelman Syndrome Therapeutics (FAST), Ovid Therapeutics, Ionis Pharmaceuticals, and F. Hoffmann-La Roche.
: This study was approved by the Institutional Review Board at RTI.
: Written consent was obtained from each participant.
